📊 AI Stock Rating — Summary

Apellis Pharmaceuticals reported revenues of approximately $200 million for Q4 2025, with a net loss of $58.95 million translating to an EPS of -$0.47. The company's free cash flow was negative, at -$13.97 million. Year-over-year growth appears mixed as the company continues to face profitability challenges. On the balance sheet, Apellis holds total assets of $1.075 billion against liabilities of $705 million, translating to a net debt position of $18.55 million, indicating moderate leverage. The company's equity stands at $370 million, showcasing its conservative capital structure. With an operating cash flow deficit of $14.2 million and limited capex at $205,000, liquidity remains a concern. Apellis has not initiated any dividend payouts, though there is minor activity in stock buybacks, amounting to $2.2 million. Analysts set a consensus price target of $33.5, showing cautious optimism about future potential. Overall, while Apellis is still unprofitable, the market's sentiment suggests a prospective upside if strategic goals are met.

AI Score Breakdown

Revenue Growth — Score: 6/10

Revenue seen at $200 million for Q4 with some growth potential but needing stabilization.

Profitability — Score: 4/10

Continued losses impact EPS and net margin; improvement needed in operational efficiency.

Cash Flow Quality — Score: 4/10

Negative free cash flow and operating cash deficits highlight liquidity challenges.

Leverage & Balance Sheet — Score: 6/10

Strong asset base with manageable leverage; net debt only $18.55 million.

Shareholder Returns — Score: 3/10

No dividends and limited buybacks suggest shareholders' returns are weak.

Analyst Sentiment & Valuation — Score: 7/10

Consensus price targets indicate potential upside, providing a positive outlook.

⚠ AI-generated — informational only, not financial advice.